NR 566 Week 6 Quiz Writer.

Week 6: Quiz Writer 1. Which of the following is not a severe symptom of Alzheimer’s disease? a. Loss of speech b. Loss of appetite; weight loss c. Changes in personality and judgment d. Loss of bladder and bowel control e. Total dependence on caregiver Answer: c. Changes in personality and judgment. Rationale: Rosenthal, L. & Burchum, J. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier. Page 448, table 20.1 classifies changes in personality and judgment as a mild symptom. 2. Which of the following statements made by the patient’s family indicates successful education for cholinesterase inhibitors? a. “We should immediately report lightheadedness as this is a severe reaction” b. “We will ensure dad has enough to each with snacks throughout the day so he can maintain his weight” c. “This treatment is sure to work for dad!” Answer: b. “We will ensure dad has enough to each with snacks throughout the day so he can maintain his weight” Rationale: Rosenthal, L. & Burchum, J. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier. Page 456. Encourage patient and family to ensure adequate intake with supplemental meals and snacks to maintain optimal weight. 3. Select all that apply. Which of the following are appropriate treatment modalities for migraine headaches? a. Beta blockers b. Triptans c. Patient education and lifestyle modifications d. Morphine e. NSAIDs f. Caffeine Answer: a. Beta blockers, b. Triptans. c. Patient education and lifestyle modifications, e. NSAIDs Rationale: Rosenthal, L. & Burchum, J. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier. Page 594. 4. What is an appropriate initial treatment for a patient with mild Parkinson’s? This study source was downloaded by from CourseH on :34:04 GMT -05:00 a. Levodopa (increases dopamine [DA] synthesis) b. Carbidopa (blocks levodopa destruction) c. Amantadine (promotes DA release) d. Selegiline (MAO-B inhibitor) Answer: d. Selegiline (MAO-B inhibitor) Rationale: Rosenthal, L. & Burchum, J. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier. Page 408. “For patients with mild symptoms, treatment can begin with an MAO-B inhibitor. MAO-B inhibitors confer mild symptomatic benefit.” 5. What is the Black Box Warning for Tolcapone (Tasmar)? a. Nephrotoxicity b. Hepatotoxicity c. Photosensitivity d. Ototoxicity Answer: b. hepatotoxicity Rationale: Rosenthal, L. & Burchum, J. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier. Page 432. “Tolcapone increases the risk for hepatotoxicity. Liver injury and liver failure may be fatal. Close monitoring is required. Tolcapone should be discontinued if clinical signs or symptoms of liver injury occur or if aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation is twice the upper range of normal.”